SKA3 promotes lung adenocarcinoma metastasis through the EGFR PI3K-Akt axis

被引:34
|
作者
Hu, Dan-dan [1 ]
Chen, Hai-ling [2 ]
Lou, Li-ming [1 ]
Zhang, Hong [1 ]
Yang, Guo-liang [3 ]
机构
[1] Zhejiang Chinese Med Univ, Zhejiang Prov Zhongshan Hosp, Dept Resp Med, Affiliated Hosp 3, Hangzhou 310000, Zhejiang, Peoples R China
[2] Zhejiang Chinese Med Univ, Guangxing Hosp, Dept Resp Med, Affiliated Hosp, Hangzhou 310000, Zhejiang, Peoples R China
[3] Zhejiang Integrated Trat & Western Med Hosp, Intern Med Oncol, Hangzhou 310000, Zhejiang, Peoples R China
基金
浙江省自然科学基金;
关键词
CANCER STATISTICS; COMPLEX; EMT; LOCALIZATION; SNAIL; AKT;
D O I
10.1042/BSR20194335
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The processes that lead to lung adenocarcinoma (LUAD) metastasis are poorly characterized. Spindle and kinetochore associated complex subunit 3 (SKA3) plays a key role in cervical cancer development, but its contribution to LUAD is unknown. Here, we found that SKA3 is overexpressed in LUAD and its expression correlates with lymph node metastasis and poor prognosis. SKA3 silencing experiments identified SKA3 as an oncogene that promotes the metastasis of LUAD cell lines and tissues. SKA3 was found to induce the expression of matrix metalloproteinase (MMP)-2, -7, and -9, which activate PI3K-AKT. SKA3 was also found to bind and activate EGFR to activate PI3K-AKT. In summary, we identify a role for SKA3 in LUAD metastasis through its ability to bind EFGR and activate PI3K-AKT signaling.
引用
收藏
页数:9
相关论文
共 50 条
  • [21] Agmatinase promotes the lung adenocarcinoma tumorigenesis by activating the NO-MAPKs-PI3K/Akt pathway
    Zhu, Hui-er
    Yin, Jia-yi
    Chen, De-xiong
    He, Sheng
    Chen, Hui
    CELL DEATH & DISEASE, 2019, 10 (11)
  • [22] Agmatinase promotes the lung adenocarcinoma tumorigenesis by activating the NO-MAPKs-PI3K/Akt pathway
    Hui-er Zhu
    Jia-yi Yin
    De-xiong Chen
    Sheng He
    Hui Chen
    Cell Death & Disease, 10
  • [23] The Role of the PI3K-AKT Pathway in Melanoma
    Davies, Michael A.
    CANCER JOURNAL, 2012, 18 (02): : 142 - 147
  • [24] LPCAT1 promotes gefitinib resistance via upregulation of the EGFR/PI3K/AKT signaling pathway in lung adenocarcinoma
    Ding, Jianghua
    Ding, Xinjing
    Leng, Zhaohui
    JOURNAL OF CANCER, 2022, 13 (05): : 1837 - 1847
  • [25] NOTCH and PI3K-AKT pathways intertwined
    Gutierrez, Alejandro
    Look, Thomas
    CANCER CELL, 2007, 12 (05) : 411 - 413
  • [26] Cancer/testis antigen LDHC promotes proliferation and metastasis by activating the PI3K/Akt/GSK-3β-signaling pathway and the in lung adenocarcinoma
    Chen, Liangyuan
    Wu, Qiumei
    Xu, Xunyu
    Yang, Caihong
    You, Jianbin
    Chen, Falin
    Zeng, Yanfen
    EXPERIMENTAL CELL RESEARCH, 2021, 398 (02)
  • [27] Correction: VersicanV1 promotes proliferation and metastasis of hepatocellular carcinoma through the activation of EGFR–PI3K–AKT pathway
    Guangyan Zhangyuan
    Fei Wang
    Haitian Zhang
    Runqiu Jiang
    Xuewen Tao
    Decai Yu
    Kangpeng Jin
    WeiWei Yu
    Yang Liu
    Yin Yin
    Jintao Shen
    Qinfeng Xu
    Wenjie Zhang
    Beicheng Sun
    Oncogene, 2020, 39 : 1388 - 1388
  • [28] Squalene epoxidase promotes pancreatic ductal adenocarcinoma tumorigenesis and drives gemcitabine resistance by activating the PI3K-Akt pathway
    Liu, Lei
    Xu, Hui
    Huang, Xinyang
    Li, Weilin
    Jin, Yixun
    Zhang, Minmin
    Wang, Lifu
    Zou, Duowu
    GUT, 2023, 72 (SUPPL_1) : A76 - A77
  • [29] Hepatocyte growth factor promotes proliferation, invasion, and metastasis of myeloid leukemia cells through PI3K-AKT and MAPK/ERK signaling pathway
    Guo, Jiang-Rui
    Li, Wei
    Wu, Yong
    Wu, Lin-Qing
    Li, Xin
    Guo, Ya-Fei
    Zheng, Xiao-Hui
    Lian, Xiao-Lan
    Huang, Hui-Fang
    Chen, Yuan-Zhong
    AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2016, 8 (09): : 3630 - 3644
  • [30] LPCAT1 promotes brain metastasis of lung adenocarcinoma by up-regulating PI3K/AKT/MYC pathway
    Wei, Chunhua
    Dong, Xiaomin
    Lu, Hui
    Tong, Fan
    Chen, Lingjuan
    Zhang, Ruiguang
    Dong, Jihua
    Hu, Yu
    Wu, Gang
    Dong, Xiaorong
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2019, 38 (1)